Buscar
18/08/2022
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Julia, M, Ruiz-Villaverde, R, Fernandez-Freire, LR, Notario, J, Llamas-Velasco, M, Ferran, M, Carrascosa, JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6)DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2.900(Q2/4D).
01/08/2022
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa
Iznardo, H, Vilarrasa, E, Roe, E, Puig, L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18116. PMID:35353931. IF:9.200(Q1/1D).
01/08/2022
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3
Reich, K, Iversen, L, Puig, L, Lambert, J, Mrowietz, U, Saday, KK, Warren, RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18068. PMID:35279890. IF:9.200(Q1/1D).
01/08/2022
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Chicharro, P, Llamas-Velasco, M, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera, R, De la Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandres-Rodriguez, O, Feltes, R, Alsina, M, Dauden, E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8)DOI:10.1111/dth.15653. PMID:35731640. IF:3.600(Q1/3D).
01/08/2022
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications
Iznardo, H, Puig, L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16)DOI:10.3390/ijms23169479. PMID:36012744. IF:5.600(Q1/3D).
04/07/2022
Comorbidity identification and referral in atopic dermatitis: a consensus document
de Frutos, JO, Carretero, G, de Lucas, R, Puig, S, Serra, E, Castro, SG, Laserna, FR, Loza, E, Silvestre-Salvador, JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5)DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2.900(Q2/4D).
01/07/2022
Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract
Amat-Samaranch, V, Lopez-Sanchez, C, Tubau, C, Puig, L, Serra-Baldrich, E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1)DOI:10.1111/cod.14101. PMID:35277988. IF:5.500(Q1/1D).
01/07/2022
Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain
Colmenero, M, del Boz, J, Wittel, JB, Roe, E, Feito-Rodriguez, M, Vicente-Villa, MA, Martin-Santiago, A, Perez, SIP, Azon, A, Valdivielso-Ramos, M, Torrelo, A, Moya, AIS, Campos-Dominguez, M, Garnacho-Saucedo, G, Defez, JMA, Casano, AV, Tercedor-Sanchez, J, Alcala, R, Gonzalez-Enseyat, MA, Giacaman, A, Hernandez-Martin, A, Garcia, MTM, Bauza, A, Dominguez-Cruz, J, Garcia-Doval, I, Grau-Perez, M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4)DOI:10.1111/pde.15015. PMID:35504688. IF:1.500(Q4/8D).